Relvar

Type: Product
Name: Relvar
First reported Sep 13 2014 - Updated Sep 13 2014 - 1 reports

Vectura Group Following A Familiar Path

Summary Vectura Group isn't well-known, but it has a broad and deep portfolio of patents and technology for the formulation, manufacture, and administration of respiratory drugs. Novartis's Ultibro and Seebri are selling well in the EU and Ultibro could ... [Published Seeking Alpha - Sep 13 2014]
First reported Sep 08 2014 - Updated Sep 08 2014 - 1 reports

GSK data presented at ERS demonstrate potential of blood eosinophil levels to help inform COPD treatment decisions

GSK today presented data at the European Respiratory Society (ERS) Congress that show blood eosinophil levels may help predict those patients with COPD who will have a greater reduction in exacerbation rates when receiving an inhaled corticosteroid (ICS) ... [Published Noodls - Sep 08 2014]
First reported Aug 21 2014 - Updated Aug 22 2014 - 1 reports

Theravance to Present at the Baird 2014 Health Care Conference

- Theravance, Inc. (NASDAQ: THRX) announced today that Michael W. Aguiar, Theravance's President and Chief Executive Officer, is scheduled to present at the Baird 2014 Health Care Conference on Thursday, September 4, 2014, at 10:50 a.m. EDT. The conference ... [Published I Stock Analyst - Aug 21 2014]
First reported Aug 21 2014 - Updated Aug 21 2014 - 2 reports

Theravance Biopharma: Neglected Spinoff Targeting A Huge Underserved Market

By Virginia Value Investor :Theravance (NASDAQ: THRX ) is probably a familiar name to many of you. The pharmaceutical company has received extensive coverage on Seeking Alpha over the years. What's surprising is how little attention their recent spin ... [Published BioPortfolio - Aug 21 2014]
First reported Aug 19 2014 - Updated Aug 19 2014 - 1 reports

Vectura Group plc : Interim Management Statement

Vectura Group plcInterim Management StatementChippenham, UK - 19 August 2014:Following the acquisition of Activaero GmbH in March 2014, the integration of the business is progressing well and Vectura's product pipeline is progressing in line with the ... [Published Investegate - Aug 19 2014]
First reported Aug 16 2014 - Updated Aug 16 2014 - 1 reports

Theravance : Appoints Michael Aguiar as President and CEO

Theravance reported that its Board of Directors has appointed Michael W. Aguiar as President and Chief Executive Officer of the Company effective August 15 , and as a member of the Board of Directors effective immediately.According to a release from the ... [Published 4 Traders - Aug 16 2014]
First reported Aug 15 2014 - Updated Aug 15 2014 - 1 reports

AWMSG recommends GSK’s Relvar Ellipta to treat asthma

All Wales Medicines Strategy Group (AWMSG) has recommended British drug-maker GlaxoSmithKline's (GSK) Relvar Ellipta to treat patients with asthma within NHS Wales, following the receipt of ministerial ratification.Relvar Ellipta was granted a license ... [Published Pharmaceutical Technology - Aug 15 2014]
First reported Aug 13 2014 - Updated Aug 13 2014 - 1 reports

Human medicines European public assessment report (EPAR): Relvar Ellipta, fluticasone furoate / vilanterol, Revision: 1, Authorised

Entities: Relvar, Ellipta, Humanism
First reported Aug 08 2014 - Updated Aug 08 2014 - 1 reports

Theravance (THRX) Incurs Narrower-than-Expected Loss in Q2

Theravance ’s ( THRX - Analyst Report ) second quarter 2014 loss of 18 cents per share was narrower than the Zacks Consensus Estimate of a loss of 53 cents. The company had incurred a loss of 37 cents per share a year ago. However, the year-ago number ... [Published Zacks.com - Aug 08 2014]
First reported Aug 07 2014 - Updated Aug 07 2014 - 1 reports

Theravance, Inc. Reports Second Quarter 2014 Financial Results

(Marketwired via COMTEX) -- Theravance, Inc. THRX +1.20% today reported financial results for the quarter ended June 30, 2014 and announced that its Board of Directors approved a $0.25 per share cash dividend to be paid on September 18, 2014 to stockholders ... [Published BioSpace - Aug 07 2014]
First reported Jul 24 2014 - Updated Jul 24 2014 - 1 reports

Surveyed EU5 Pulmonologists Expect that Relvar, the First Once-Daily LABA/ICS FDC, Will Experience Healthy Uptake in Asthma

BURLINGTON, Mass., July 24, 2014 /PRNewswire/ -- Decision Resources Group finds that, for the treatment of asthma, pulmonologists in the EU5 countries (France, Germany, Italy, Spain and the United Kingdom) hold a generally positive view of the first ... [Published PR Newswire: General Business - Jul 24 2014]
Entities: Relvar, Asthma, Experience
First reported Jun 11 2014 - Updated Jun 12 2014 - 1 reports

GSK and Theravance Announce Positive Data From Two Studies Evaluating the Efficacy and Safety of Incruse(TM) Ellipta(R) When Added to Relvar(R)/Breo(R) Ellipta(R) in Patients With COPD

LONDON, UNITED KINGDOM and SOUTH SAN FRANCISCO, CA--(Marketwired - Jun 11, 2014) - GlaxoSmithKline plc (LSE: GSK) (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced positive results from two phase III studies, which showed that patients ... [Published Marketwire - Breaking News Releases - Jun 11 2014]

Quotes

...an important role in guiding effective COPD management," said Neil Barnes , Global Franchise Medical Head of Respiratory at Glaxo in a statement. "We believe it is important that further work, including prospective studies, is undertaken to generate more evidence about the promising role of blood eosinophil levels as an indicator of response to an ICS-containing regimen.”"
Neil Barnes, Global Franchise Medical Head, Respiratory, GSK said: "COPD is a heterogeneous disease and enhancing our understanding of how individual patients respond to different treatments is critical to allow treatment to be tailored to their specific needs, with the ultimate aim of improving outcomes."
...By tracking the size and price of each montha'a "s short transactions, SQUEEZETRIGGER.COM provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin."
...On earnings calls they typically refer to this as the " triple therapy ". It combines an inhaled corticosteroid (used to control asthma), a long acting muscanrinic antagonist (for COPD) and a long acting beta2-adrenergic agonist (for muscle relaxation)."

More Content

All (28) | News (22) | Reports (0) | Blogs (6) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Vectura Group Following A Familiar Path [Published Seeking Alpha - Sep 13 2014]
GlaxoSmithKline : Glaxo Presents Data From Bloo... [Published 4 Traders - Sep 08 2014]
GSK data presented at ERS demonstrate potential... [Published Noodls - Sep 08 2014]
LF, OSTK, ORRF, GOL, THRX, GPN Are Seasonally R... [Published TradingCharts.com - Sep 08 2014]
Theravance to Present at the Baird 2014 Health ... [Published I Stock Analyst - Aug 21 2014]
Theravance Biopharma: Neglected Spinoff Targeti... [Published BioPortfolio - Aug 21 2014]
Theravance Biopharma: Neglected Spinoff Targeti... [Published Seeking Alpha - Aug 21 2014]
Vectura Group plc : Interim Management Statement [Published Investegate - Aug 19 2014]
Theravance : Appoints Michael Aguiar as Preside... [Published 4 Traders - Aug 16 2014]
AWMSG recommends GSK’s Relvar Ellipta to treat ... [Published Pharmaceutical Technology - Aug 15 2014]
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Aug 13 2014]
Theravance (THRX) Incurs Narrower-than-Expected... [Published Zacks.com - Aug 08 2014]
Theravance, Inc. Reports Second Quarter 2014 Fi... [Published BioSpace - Aug 07 2014]
Surveyed EU5 Pulmonologists Expect that Relvar,... [Published PR Newswire: General Business - Jul 24 2014]
Theravance, Inc. Appoints Theodore J. Witek, Jr... [Published Marketwire - Breaking News Releases - Jul 02 2014]
Theravance, Inc. Appoints George B. Abercrombie... [Published Marketwire - Breaking News Releases - Jun 12 2014]
GSK and Theravance Announce Positive Data From ... [Published Marketwire - Breaking News Releases - Jun 11 2014]
Interim Management Statement [Published TrustNet - May 16 2014]
1st Quarter Results [Published TrustNet - Apr 30 2014]
Welcome tonic [Published Engineer Online - Apr 23 2014]
Proposed Placing and Open Offer to Raise ?112m [Published TrustNet - Mar 31 2014]
Anoro receives Positive Opinion from the CHMP [Published Vitec Group - Mar 27 2014]
Patient Recruitment Completes in Landmark RELVA... [Published Marketwire - Breaking News Releases - Mar 13 2014]
Final Results [Published TrustNet - Feb 05 2014]
ANORO ELLIPTA RECEIVES REGULATORY APPROVAL IN US [Published TrustNet - Dec 19 2013]
Skyepharma Capital Markets Meeting and fliutifo... [Published SkyePharma - Dec 19 2013]
GSK Invests in UK Manufacturing [Published Pharmaceutical Executive - Dec 16 2013]
Deep Breadth: GSK Doubles Down on COPD and Asthma [Published Pharmaceutical Executive - Dec 12 2013]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Aug 13 2014]
Surveyed EU5 Pulmonologists Expect that Relvar,... [Published PR Newswire: General Business - Jul 24 2014]
BURLINGTON, Mass., July 24, 2014 /PRNewswire/ -- Decision Resources Group finds that, for the treatment of asthma, pulmonologists in the EU5 countries (France, Germany, Italy, Spain and the United Kingdom) hold a generally positive view of the first ...
Theravance, Inc. Appoints Theodore J. Witek, Jr... [Published Marketwire - Breaking News Releases - Jul 02 2014]
SOUTH SAN FRANCISCO, CA--(Marketwired - Jul 2, 2014) - Theravance, Inc. (NASDAQ: THRX) ("Theravance"), A Royalty Management Company, today announced the appointment of Theodore J. Witek, Jr. as Senior Vice President Corporate Partnerships, Clinical ...
Theravance, Inc. Appoints George B. Abercrombie... [Published Marketwire - Breaking News Releases - Jun 12 2014]
SOUTH SAN FRANCISCO, CA--(Marketwired - Jun 12, 2014) - Theravance, Inc. (NASDAQ: THRX) ("Theravance"), a royalty management company, today announced the appointment of George B. Abercrombie, Senior Vice President, Corporate Partnerships, Commercial. ...
GSK and Theravance Announce Positive Data From ... [Published Marketwire - Breaking News Releases - Jun 11 2014]
LONDON, UNITED KINGDOM and SOUTH SAN FRANCISCO, CA--(Marketwired - Jun 11, 2014) - GlaxoSmithKline plc (LSE: GSK) (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced positive results from two phase III studies, which showed that patients ...
1 2
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.